Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-05-19 Sale |
2023-05-23 08:06 am |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
4,300 | $216.91 | $932,707 | 12,946 (Direct) |
View |
| 2023-02-21 Sale |
2023-02-23 09:54 am |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
8,000 | $250.58 | $2,004,675 | 13,369 (Direct) |
View |
| 2021-05-06 Sale |
2021-05-10 08:21 am |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
2,500 | $276.55 | $691,375 | 7,844 (Direct) |
View |
| 2020-11-04 Sale |
2020-11-06 09:06 am |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
1,500 | $214.14 | $321,204 | 7,698 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-05-19 Exercise |
2023-05-23 08:06 am |
2021-02-04 2030-02-03 |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
4,300 | $0 | 12,946 (Direct) |
View |
| 2023-05-19 Exercise |
2023-05-23 08:06 am |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
4,300 | $182.51 | 12,946 (Direct) |
View |
| 2023-03-30 Option Award |
2023-04-03 10:13 am |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
6,763 | $0 | 12,946 (Direct) |
View |
| 2023-03-30 Tax Withholding |
2023-04-03 10:13 am |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
2,886 | $224.7 | 12,946 (Direct) |
View |
| 2023-02-21 Exercise |
2023-02-23 09:54 am |
2021-02-04 2030-02-03 |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
3,000 | $0 | 13,369 (Direct) |
View |
| 2023-02-21 Exercise |
2023-02-23 09:54 am |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
3,000 | $182.51 | 13,369 (Direct) |
View |
| 2023-02-11 Exercise |
2023-02-14 2:57 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
483 | $0 | 17,070 (Direct) |
View |
| 2023-02-13 Tax Withholding |
2023-02-14 2:57 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
142 | $248.13 | 17,070 (Direct) |
View |
| 2023-02-07 Option Award |
2023-02-09 12:02 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
6,590 | $0 | 8,484 (Direct) |
View |
| 2023-02-04 Exercise |
2023-02-07 2:51 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
560 | $0 | 15,622 (Direct) |
View |
| 2023-02-06 Tax Withholding |
2023-02-07 2:51 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
164 | $244.5 | 15,622 (Direct) |
View |
| 2023-02-02 Tax Withholding |
2023-02-06 3:45 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
141 | $254.99 | 15,786 (Direct) |
View |
| 2023-02-02 Exercise |
2023-02-06 3:45 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
443 | $0 | 15,786 (Direct) |
View |
| 2022-11-01 Exercise |
2022-11-03 5:00 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
2,007 | $0 | 15,927 (Direct) |
View |
| 2022-11-01 Tax Withholding |
2022-11-03 5:00 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
892 | $222.56 | 15,927 (Direct) |
View |
| 2022-03-28 Tax Withholding |
2022-03-29 12:04 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
1,648 | $276.42 | 11,915 (Direct) |
View |
| 2022-03-27 Option Award |
2022-03-29 12:04 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
3,707 | $0 | 11,915 (Direct) |
View |
| 2022-02-12 Exercise |
2022-02-15 4:42 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
317 | $0 | 25,081 (Direct) |
View |
| 2022-02-11 Option Award |
2022-02-15 4:42 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
6,550 | $0 | 25,081 (Direct) |
View |
| 2022-02-14 Tax Withholding |
2022-02-15 4:42 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
108 | $272.68 | 25,081 (Direct) |
View |
| 2022-02-04 Exercise |
2022-02-08 11:13 am |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
560 | $0 | 13,418 (Direct) |
View |
| 2022-02-04 Tax Withholding |
2022-02-08 11:13 am |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
165 | $277.48 | 13,418 (Direct) |
View |
| 2022-02-02 Exercise |
2022-02-04 09:44 am |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
443 | $0 | 13,583 (Direct) |
View |
| 2022-02-02 Tax Withholding |
2022-02-04 09:44 am |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
144 | $273.18 | 13,583 (Direct) |
View |
| 2021-11-01 Exercise |
2021-11-03 11:47 am |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
2,007 | $0 | 13,727 (Direct) |
View |
| 2021-11-01 Tax Withholding |
2021-11-03 11:47 am |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
898 | $288.78 | 13,727 (Direct) |
View |
| 2021-04-03 Exercise |
2021-04-06 12:18 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
1,010 | $0 | 17,125 (Direct) |
View |
| 2021-04-03 Tax Withholding |
2021-04-06 12:18 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
452 | $252.67 | 17,125 (Direct) |
View |
| 2021-03-27 Option Award |
2021-03-30 6:42 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
2,104 | $0 | 9,786 (Direct) |
View |
| 2021-03-27 Tax Withholding |
2021-03-30 6:42 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
790 | $251.58 | 9,786 (Direct) |
View |
| 2021-02-12 Tax Withholding |
2021-02-17 4:25 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
180 | $238.26 | 24,371 (Direct) |
View |
| 2021-02-12 Exercise |
2021-02-17 4:25 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
581 | $0 | 24,371 (Direct) |
View |
| 2021-02-04 Exercise |
2021-02-08 3:39 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
560 | $0 | 16,443 (Direct) |
View |
| 2021-02-04 Tax Withholding |
2021-02-08 3:39 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
187 | $223.78 | 16,443 (Direct) |
View |
| 2021-02-02 Option Award |
2021-02-04 5:14 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
5,930 | $0 | 13,532 (Direct) |
View |
| 2020-11-02 Tax Withholding |
2020-11-04 5:40 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
895 | $207.23 | 16,800 (Direct) |
View |
| 2020-11-02 Exercise |
2020-11-04 5:40 pm |
N/A N/A |
LABORATORY CORP OF AMERICA HOLDINGS | LH | Kirchgraber Paul R CEO, Covance Drug Development |
2,006 | $0 | 16,800 (Direct) |
View |